The eptinezumab:CGRP complex structure – the role of conformational changes in binding stabilization

References

• Stovner LJ, Nichols E, Steiner TJ, GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17:(11):954–976.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–566.
   PubMed Web of Science ®Google Scholar
• Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563–578.
   PubMed Web of Science ®Google Scholar
• Sumelahti M-L, Sumanen M, Sumanen MS, et al. My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland. J Headache Pain. 2020;21(1):118.
   PubMed Web of Science ®Google Scholar
• Simić S, Rabi-Žikić T, Villar JR, et al. Impact of individual headache types on the work and work efficiency of headache sufferers. Int J Environ Res Public Health. 2020;17(18):6918.
   PubMed Web of Science ®Google Scholar
• Adelborg K, Szepligeti SK, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96.
   PubMed Web of Science ®Google Scholar
• Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610.
   PubMed Web of Science ®Google Scholar
• Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339(oct27 1):b3914.
   PubMed Web of Science ®Google Scholar
• McLean G, Mercer SW. Chronic migraine, comorbidity, and socioeconomic deprivation: cross-sectional analysis of a large nationally representative primary care database. J Comorb. 2017;7(1):89–95.
   PubMedGoogle Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24(2):91–100.
   PubMed Web of Science ®Google Scholar
• Iyengar S, Johnson KW, Ossipov MH, et al. CGRP and the trigeminal system in migraine. Headache. 2019;59(5):659–681.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA. Identifying new antimigraine targets: lessons from molecular biology. Trends Pharmacol Sci. 2021;42(4):217–225.
   PubMed Web of Science ®Google Scholar
• Baker B, Schaeffler B, and Cady R, et al. Rational design of a monoclonal antibody (mAB) inhibiting calcitonin gene-related peptide (CGRP), ALD403, intended for the prevention of migraine (p2.155). Neurology. 2017; 882:2–155.
   Google Scholar
• VYEPTI [package insert]. Vyepti Prescribing Information. (Bothell WA): Lundbeck Seattle BioPharmaceuticals, Inc.; 2021.
   Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075–1085.
   PubMed Web of Science ®Google Scholar
• Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–254.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology. 2020;94(13):e1365–e1377.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study. J Headache Pain. 2020;21(1):120.
   PubMed Web of Science ®Google Scholar
• Latham J, Karasek C, Ojala E, et al. Characterization of the binding of three anti-CGRP antibodies effective in preventing migraine: a comparative case study of ALD403, LY-2951742, TEV-48125. Cephalalgia. 2016;36:144.
   Web of Science ®Google Scholar
• Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59(Suppl S2):20–32.
   PubMedGoogle Scholar
• Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr. 2010;66(2):125–132.
   PubMedGoogle Scholar
• Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326.
   PubMed Web of Science ®Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, et al. Phaser crystallographic software. J Appl Crystallogr. 2007;40(4):658–674.
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta crystallographica section D: biological crystallography. 2004;60(12):2126–2132
   PubMedGoogle Scholar
• Vagin AA, Steiner RA, Lebedev AA, et al. REFMAC 5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallographica Section D: Biological Crystallography. 2004;60(12):2184–2195.
   PubMedGoogle Scholar
• Barlow KA, Thompson SÓC, Thompson S, et al. Flex ddG: Rosetta Ensemble-Based Estimation of Changes in Protein-Protein Binding Affinity upon Mutation. J Phys Chem B. 2018;122(21):5389–5399.
   PubMed Web of Science ®Google Scholar
• Abel R, Young T, Farid R, et al. Role of the active-site solvent in the thermodynamics of Factor Xa ligand binding. J Am Chem Soc. 2008;130(9):2817–2831.
   PubMed Web of Science ®Google Scholar
• Young T, Abel R, Kim B, et al. Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding. Proc Natl Acad Sci. 2007;104(3):808–813.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang X, Cao D. The role of shape complementarity in the protein-protein interactions. Sci Rep. 2013;3(1):3271.
   PubMedGoogle Scholar
• Garcia-Martinez LF, Raport CJ, Ojala EW, et al. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. JPET. 2020;374(1):93–103.
   PubMed Web of Science ®Google Scholar
• Liang Y-L, Khoshouei M, Deganutti G, et al. Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature. 2018;561(7724):492–497.
   PubMed Web of Science ®Google Scholar